• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

能否将公平性问题纳入成本效益分析?系统评价。

Can cost-effectiveness analysis integrate concerns for equity? Systematic review.

机构信息

Departement of Health Administration, University of Montreal, Montreal, Canada.

出版信息

Int J Technol Assess Health Care. 2012 Apr;28(2):125-32. doi: 10.1017/S0266462312000050. Epub 2012 Apr 12.

DOI:10.1017/S0266462312000050
PMID:22494637
Abstract

OBJECTIVES

The aim of this study was to promote approaches to health technology assessment (HTA) that are both evidence-based and values-based. We conducted a systematic review of published studies describing formal methods to consider equity in the context of cost-effectiveness analysis (CEA).

METHODS

Candidate studies were identified through an unrestricted search of the Pub Med and EMBASE databases. The search closed on January 20, 2011. We identified additional studies by consulting experts and checking article bibliographies. Two authors independently reviewed each candidate study to determine inclusion and extracted data from studies retained for review. In addition to documenting methods, data extraction identified implicit and explicit notions of fairness. Data were synthesized in narrative form. Study quality was not assessed.

RESULTS

Of the 695 candidate articles, 51 were retained for review. We identified three broad methods to facilitate quantitative consideration of equity concerns in economic evaluation: integration of distributional concerns through equity weights and social welfare functions, exploration of the opportunity costs of alternative policy options through mathematical programming, and multi-criteria decision analysis.

CONCLUSIONS

Several viable techniques to integrate equity concerns within CEA now exist, ranging from descriptive approaches to the quantitative methods studied in this review. Two obstacles at the normative level have impeded their use in decision making to date: the multiplicity of concepts and values discussed under the rubric of equity, and the lack of a widely accepted normative source on which to ground controversial value choices. Clarification of equity concepts and attention to procedural fairness may strengthen use of these techniques in HTA decision making.

摘要

目的

本研究旨在促进基于证据和价值的卫生技术评估(HTA)方法。我们对描述在成本效益分析(CEA)背景下考虑公平性的正式方法的已发表研究进行了系统回顾。

方法

通过对 Pub Med 和 EMBASE 数据库的无限制搜索来确定候选研究。搜索于 2011 年 1 月 20 日关闭。我们通过咨询专家和检查文章参考文献来确定其他研究。两位作者独立审查了每个候选研究,以确定是否纳入,并从保留进行审查的研究中提取数据。除了记录方法外,数据提取还确定了公平的隐含和显式概念。数据以叙述形式综合。未评估研究质量。

结果

在 695 篇候选文章中,有 51 篇被保留进行综述。我们确定了三种广泛的方法,以促进在经济评估中定量考虑公平问题:通过公平权重和社会福利函数整合分配问题,通过数学规划探索替代政策选择的机会成本,以及多标准决策分析。

结论

目前存在几种将公平问题纳入 CEA 的可行技术,从描述性方法到本综述中研究的定量方法不等。在规范层面上存在两个障碍,阻碍了它们在决策中的应用:公平概念下讨论的概念和价值观的多样性,以及缺乏一个广泛接受的规范来源来为有争议的价值选择提供依据。澄清公平概念并关注程序公平性可能会加强这些技术在 HTA 决策中的应用。

相似文献

1
Can cost-effectiveness analysis integrate concerns for equity? Systematic review.能否将公平性问题纳入成本效益分析?系统评价。
Int J Technol Assess Health Care. 2012 Apr;28(2):125-32. doi: 10.1017/S0266462312000050. Epub 2012 Apr 12.
2
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
3
A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.TNF-α 抑制剂(阿达木单抗和英夫利昔单抗)治疗克罗恩病的系统评价和经济评估。
Health Technol Assess. 2011 Feb;15(6):1-244. doi: 10.3310/hta15060.
4
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
5
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
6
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.戈谢病酶替代疗法的临床疗效和成本效益:一项系统评价。
Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. doi: 10.3310/hta10240.
7
Management of frozen shoulder: a systematic review and cost-effectiveness analysis.冻结肩的治疗:系统评价和成本效益分析。
Health Technol Assess. 2012;16(11):1-264. doi: 10.3310/hta16110.
8
Decision aids for people facing health treatment or screening decisions.为面临医疗治疗或筛查决策的人们提供的决策辅助工具。
Cochrane Database Syst Rev. 2011 Oct 5(10):CD001431. doi: 10.1002/14651858.CD001431.pub3.
9
Education support services for improving school engagement and academic performance of children and adolescents with a chronic health condition.改善患有慢性病的儿童和青少年的学校参与度和学业成绩的教育支持服务。
Cochrane Database Syst Rev. 2023 Feb 8;2(2):CD011538. doi: 10.1002/14651858.CD011538.pub2.
10
Effects of consumers and health providers working in partnership on health services planning, delivery and evaluation.消费者和医疗服务提供者合作对卫生服务规划、提供和评估的影响。
Cochrane Database Syst Rev. 2021 Sep 15;9(9):CD013373. doi: 10.1002/14651858.CD013373.pub2.

引用本文的文献

1
Considerations when applying equity weights within economic evaluation when making drug reimbursement decisions.在做出药品报销决策时,在经济评估中应用公平权重时的考量因素。
Health Econ Rev. 2024 Nov 13;14(1):90. doi: 10.1186/s13561-024-00556-w.
2
Health Equity Considerations in Cost-Effectiveness Analysis: Insights from an Umbrella Review.成本效益分析中的健康公平考量:一项系统性综述的见解
Clinicoecon Outcomes Res. 2024 Aug 20;16:581-596. doi: 10.2147/CEOR.S471827. eCollection 2024.
3
Inequities in kidney health and kidney care.肾脏健康和肾脏护理方面的不平等。
Nat Rev Nephrol. 2023 Nov;19(11):694-708. doi: 10.1038/s41581-023-00745-6. Epub 2023 Aug 14.
4
Equity in Economic Evaluations of Early Childhood Development Interventions in Low-and Middle-Income Countries: Scoping Review.经济评估中的公平性:对中低收入国家幼儿发展干预措施的范围综述。
Matern Child Health J. 2023 Jun;27(6):1009-1029. doi: 10.1007/s10995-023-03650-3. Epub 2023 Apr 10.
5
Equity-Informative Economic Evaluations of Vaccines: A Systematic Literature Review.疫苗的公平性信息经济评估:系统文献综述
Vaccines (Basel). 2023 Mar 9;11(3):622. doi: 10.3390/vaccines11030622.
6
Expected cost effectiveness of the fourth dose of COVID-19 vaccine against the omicron variant of COVID-19: a preliminary report.新冠病毒奥密克戎变异株第四剂新冠疫苗的预期成本效益:初步报告
Int J Physiol Pathophysiol Pharmacol. 2022 Aug 15;14(4):272-275. eCollection 2022.
7
A Systematic Review of Economic Evaluations of COVID-19 Interventions: Considerations of Non-Health Impacts and Distributional Issues.COVID-19 干预措施的经济评价系统综述:考虑非健康影响和分配问题。
Value Health. 2022 Aug;25(8):1298-1306. doi: 10.1016/j.jval.2022.02.003. Epub 2022 Apr 6.
8
Incorporating Equity Concerns in Cost-Effectiveness Analyses: A Systematic Literature Review.将公平性问题纳入成本效益分析中:系统文献回顾。
Pharmacoeconomics. 2022 Jan;40(1):45-64. doi: 10.1007/s40273-021-01094-7. Epub 2021 Oct 29.
9
Public Health Interventions with Harms and Benefits: A Graphical Framework for Evaluating Tradeoffs.公共卫生干预措施的利弊:权衡取舍的图形框架。
Med Decis Making. 2020 Nov;40(8):978-989. doi: 10.1177/0272989X20960458. Epub 2020 Sep 30.
10
Estimating Health Adjusted Age at Death (HAAD).估算健康调整死亡年龄(HAAD)。
PLoS One. 2020 Jul 14;15(7):e0235955. doi: 10.1371/journal.pone.0235955. eCollection 2020.